Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 451

1.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
2.

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Namdar M, Perez G, Ngo L, Marks PA.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29.

3.

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.

Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS.

Invest New Drugs. 2012 Aug;30(4):1434-42. doi: 10.1007/s10637-011-9718-1. Epub 2011 Jul 20.

PMID:
21773733
4.
5.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

6.

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):389-98. doi: 10.1007/s00280-010-1495-6. Epub 2010 Nov 3.

PMID:
21046105
7.

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K.

Br J Cancer. 2007 Nov 19;97(10):1344-53. Epub 2007 Nov 13.

8.

Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.

Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB.

J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039.

PMID:
22703804
9.

A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS.

Biomed Pharmacother. 2013 Jun;67(5):407-15. doi: 10.1016/j.biopha.2013.01.006. Epub 2013 Feb 16.

PMID:
23583193
10.
11.

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A.

Mol Cancer Ther. 2009 Nov;8(11):3075-87. doi: 10.1158/1535-7163.MCT-09-0254. Epub 2009 Nov 3.

12.
13.
14.

Dual-acting histone deacetylase-topoisomerase I inhibitors.

Guerrant W, Patil V, Canzoneri JC, Yao LP, Hood R, Oyelere AK.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3283-7. doi: 10.1016/j.bmcl.2013.03.108. Epub 2013 Apr 4.

15.
16.

Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Guerrant W, Patil V, Canzoneri JC, Oyelere AK.

J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.

17.

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2006 Sep 1;12(17):5199-206.

18.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

19.

Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.

Pourpak A, Landowski TH, Dorr RT.

J Pharmacol Exp Ther. 2007 Jun;321(3):1109-17. Epub 2007 Mar 9.

20.

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA.

Clin Cancer Res. 2001 Apr;7(4):962-70.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk